Time from melanoma diagnosis to surgery is commonly delayed in Medicare patients
the ONA take:
Surgery is delayed in 1 in 5 Medicare patients with melanoma, according to a Yale study. Melanoma is the leading cause of new cancer diagnoses in the United States.
In this population-based analysis of delay of surgery among Medicare patients with melanoma, culled from the Surveillance, Epidemiology, and End Result-Medicare database, the researchers reviewed more than 32,000 cases of melanoma diagnosis in Medicare patients.
No gold standard exists on time from diagnosis to study; however, the recommended timeframe from between diagnosis and surgery is less than 6 weeks.
This study found that 22% of patients waited longer than 1.5 months for surgery, and surgery was delayed more than 3 months in 8% of patients. Delays were most common when the treating clinician was not a dermatologist (eg, a primary care physician or general surgeon).
In addition, study findings revealed a significant difference in timing from melanoma diagnosis to surgery for Medicare patients.
The researchers suggest further studies should seek to identify reasons for the delay to surgery and to consider how coordination between care providers can be improved.
Surgery is delayed in 1 in 5 Medicare patients with melanoma.
Sign Up for Free e-newsletters
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- ASCO Endorses SIO Guideline for Integrative Therapies in Breast Cancer
- Seeking Reliable Information on Herbal Products
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Adhering to Cytoreductive Therapy Use May Improve Outcomes in Polycythemia Vera
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|